David Pirlot

Array ( [id] => 18361123 [patent_doc_number] => 20230142714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => KETONE INHIBITORS OF LYSINE GINGIPAIN [patent_app_type] => utility [patent_app_number] => 17/740260 [patent_app_country] => US [patent_app_date] => 2022-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 375 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17740260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18109508 [patent_doc_number] => 20230002388 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS [patent_app_type] => utility [patent_app_number] => 17/739855 [patent_app_country] => US [patent_app_date] => 2022-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67881 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17739855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19889043 [patent_doc_number] => 20250114355 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-10 [patent_title] => TREATING LIVER DISEASE [patent_app_type] => utility [patent_app_number] => 18/289047 [patent_app_country] => US [patent_app_date] => 2022-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18289047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18153062 [patent_doc_number] => 11566023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-31 [patent_title] => Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof [patent_app_type] => utility [patent_app_number] => 17/738216 [patent_app_country] => US [patent_app_date] => 2022-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 40 [patent_no_of_words] => 46075 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17738216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18604646 [patent_doc_number] => 11746095 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Inhibtors of RAF kinases [patent_app_type] => utility [patent_app_number] => 17/738327 [patent_app_country] => US [patent_app_date] => 2022-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26114 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17738327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265204 [patent_doc_number] => 20240208903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => ACID ADDITION SALTS OF (S)-3-(2,5-DIMETHOXY-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE AND (S)-3-(2-METHOXY-5-(METHYLTHIO)-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE, SPECIFIC POLYMORPHS THEREOF AND METHODS FOR THEIR MANUFACTURE [patent_app_type] => utility [patent_app_number] => 18/556295 [patent_app_country] => US [patent_app_date] => 2022-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19658426 [patent_doc_number] => 20240425491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS [patent_app_type] => utility [patent_app_number] => 18/288711 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88649 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18288711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345180 [patent_doc_number] => 20240254143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => OREXIN RECEPTOR AGONISTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/558245 [patent_app_country] => US [patent_app_date] => 2022-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50881 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18558245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19210679 [patent_doc_number] => 11999727 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Compounds and methods of use [patent_app_type] => utility [patent_app_number] => 17/732846 [patent_app_country] => US [patent_app_date] => 2022-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 481377 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 483 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17732846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18216400 [patent_doc_number] => 11591322 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Certain chemical compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/731943 [patent_app_country] => US [patent_app_date] => 2022-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 29798 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 704 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17731943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18187497 [patent_doc_number] => 11578066 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-02-14 [patent_title] => Fluoroalkyl-oxadiazoles and uses thereof [patent_app_type] => utility [patent_app_number] => 17/731949 [patent_app_country] => US [patent_app_date] => 2022-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58677 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17731949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19279870 [patent_doc_number] => 20240216342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => BLOOD CARNITINE-INCREASING AGENT [patent_app_type] => utility [patent_app_number] => 18/556912 [patent_app_country] => US [patent_app_date] => 2022-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830001 [patent_doc_number] => 20220267305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/727386 [patent_app_country] => US [patent_app_date] => 2022-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 654 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17727386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18271634 [patent_doc_number] => 20230092876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 17/724629 [patent_app_country] => US [patent_app_date] => 2022-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17724629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982538 [patent_doc_number] => 20220348574 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => PARP1 INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/723929 [patent_app_country] => US [patent_app_date] => 2022-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55312 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 639 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17723929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982530 [patent_doc_number] => 20220348566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => Novel Heteroaryl Aminopropanol Derivatives [patent_app_type] => utility [patent_app_number] => 17/716423 [patent_app_country] => US [patent_app_date] => 2022-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43326 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17716423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19722700 [patent_doc_number] => 20250025451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-23 [patent_title] => TREATMENT OF CANCER WITH KDM4 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/554283 [patent_app_country] => US [patent_app_date] => 2022-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318196 [patent_doc_number] => 20240239738 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => (S)-3-AMINO-4-(DIFLUOROMETHYLENE)CYCLOHEXENE AND CYCLOHEXANE CARBOXYLIC ACID AND USES THEREOF AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE (hOAT) [patent_app_type] => utility [patent_app_number] => 18/554265 [patent_app_country] => US [patent_app_date] => 2022-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170991 [patent_doc_number] => 20240156965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => DICHALCOGENIDE PRODRUGS [patent_app_type] => utility [patent_app_number] => 18/554092 [patent_app_country] => US [patent_app_date] => 2022-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30917 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281485 [patent_doc_number] => 20240217959 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => New (Homo)Piperidinyl Heterocycles as Sigma Ligands [patent_app_type] => utility [patent_app_number] => 18/554195 [patent_app_country] => US [patent_app_date] => 2022-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10654 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554195 [rel_patent_id] =>[rel_patent_doc_number] =>)